Tech Company Financing Transactions
Gemin X Pharmaceuticals Funding Round
Gemin X Pharmaceuticals, operating out of Malvern, received $8 million from Valence Life Sciences, Sanderling Ventures and private investors.
Transaction Overview
Company Name
Announced On
8/5/2010
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Series E
Investors
Valence Life Sciences (Lead Investor) (Eric Roberts)
Sanderling Ventures (Robert McNeil)
Proceeds Purpose
The Series E funding follows on a growing body of positive clinical data from our randomized, controlled Phase 2b study of obatoclax for the first-line treatment of extensive stage small cell lung cancer (ES-SCLC), and we look forward to submitting this data for presentation at an upcoming medical conference.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
400 Chesterfield Parkway 100
Malvern, PA 19355
USA
Malvern, PA 19355
USA
Phone
Website
Email Address
Overview
Gemin X Pharmaceuticals Inc. specializes in the discovery and development of novel small-molecule cancer therapeutics based on the regulation of apoptosis, the body's natural ability to destroy injured or damaged cells.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Dolan
Chief Financial Officer
Michael Dixon
Chief Medical Officer
Jean Viallet
Chief Scientific Officer
Gordon Shore
Vice President
Mark Berger
VP - Bus. Development
Art Fratamico
VP - Operations
Edwina Wyatt-Knowles
Browse more venture capital transactions:
Prev: 8/4/2010: Maskless Lithography venture capital transaction
Next: 8/5/2010: Laguna Pharmaceuticals venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs